BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1011 related articles for article (PubMed ID: 8893900)

  • 21. Paclitaxel and doxorubicin in metastatic breast cancer.
    Gehl J; Boesgaard M; Paaske T; Jensen BV; Dombernowsky P
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):35-8. PubMed ID: 8996596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The current state of adjuvant therapy for breast cancer: focus on paclitaxel.
    Hudis CA
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):1-5. PubMed ID: 10190778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer.
    Seidman AD; Hudis CA; Fennelly D; Raptis G; Baselga J; Norton L
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):108-16. PubMed ID: 7481852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
    Kennedy MJ; Donehower RC; Rowinsky EK
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):23-7. PubMed ID: 7543700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
    Klaassen U; Wilke H; Müller C; Borquez D; Harstrick A; Seeber S
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future developments for paclitaxel in the treatment of breast cancer.
    Bonadonna G
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):65-8. PubMed ID: 8629041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
    Hortobagyi GN; Willey J; Rahman Z; Holmes FA; Theriault RL; Buzdar AU
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-65-S17-68. PubMed ID: 9374097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel in the treatment of esophageal cancer.
    Weiner LM
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):106-8. PubMed ID: 10190790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial.
    Nicholson B; Paul D; Shyr Y; Garrett M; Hande KR; Johnson DH
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-20-S11-23. PubMed ID: 9314294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
    Buzdar AU; Hortobagyi GN; Asmar L; Theriault RL; Rahman Z; McNeese M; Singletary S; Ames F
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-31-S17-34. PubMed ID: 9374089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of paclitaxel in the therapy of bladder cancer.
    Roth BJ
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):33-40. PubMed ID: 7481859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel in salvage therapy for germ cell tumors.
    Motzer RJ
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.